TREATMENT OF VITREOMACULAR TRACTION WITH INTRAVITREAL PERFLUOROPROPANE (C3F8) INJECTION.
OBJECTIVE
To assess the posterior vitreous release rates following a single, office-based intravitreal injection of expansile gas in treating vitreomacular traction.


METHODS
Thirty eyes of 29 consecutive patients with symptomatic vitreomacular traction received a single, office-based intravitreal injection of up to 0.3 mL of 100% perfluoropropane (C3F8).


RESULTS
Overall, vitreomacular traction release occurred in 25 of 30 eyes by the final follow-up visit (83% final release rate); furthermore, 90% (9 of 10 eyes) with diabetes mellitus released, 83% (5 of 6 eyes) with concurrent epiretinal membrane released, and 83% (5 of 6 eyes) previously treated with ocriplasmin released. Vitreomacular traction release occurred overnight in some patients and was documented on spectral domain optical coherence tomography at an average of 13 days (range, 1-62 days). The phakic release rate was 89% (16 of 18 eyes) versus a 75% pseudophakic release rate (9 of 12 eyes) (P = 0.3173). Ellipsoid zone changes on spectral domain optical coherence tomography occurred in 1 of 30 gas-treated eyes. One patient developed pupillary block.


CONCLUSIONS
Office-based intravitreal injection of C3F8 offers an inexpensive and effective treatment for vitreomacular traction, including for patients who underwent previous ocriplasmin administration and in patients with diabetes mellitus or epiretinal membrane.
California Retina Consultants and Research Foundation, Santa Barbara, California.
Nathan C
NC
Steinle
Dilsher S
DS
Dhoot
Carlos
C
Quezada Ruiz
Alessandro A
AA
Castellarin
Dante J
DJ
Pieramici
Robert F
RF
See
Steven C
SC
Couvillion
Maʼan A
MA
Nasir
Robert L
RL
Avery
D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media / Q000008:administration & dosage*; D058450:Endotamponade / Q000379:methods; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000188:drug therapy*; D012189:Retrospective Studies; D014792:Visual Acuity; D020255:Vitreous Detachment / Q000188:drug therapy*
D003287:Contrast Media; D005466:Fluorocarbons; C042852:perflutren